25 XP   0   0   10

Janux Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Janux Therapeutics Inc together

PenkeI guess you are interested in Janux Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Janux Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Janux Therapeutics Inc

I send you an email if I find something interesting about Janux Therapeutics Inc.

Quick analysis of Janux Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Janux Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$6.67
Expected worth in 1 year
$7.12
How sure are you?
15.4%

+ What do you gain per year?

Total Gains per Share
$0.46
Return On Investment
1.0%

For what price can you sell your share?

Current Price per Share
$47.96
Expected price per share
$23.64 - $58.69
How sure are you?
50%

1. Valuation of Janux Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

$47.96

Intrinsic Value Per Share

$-13.76 - $-16.24

Total Value Per Share

$-7.09 - $-9.57

2. Growth of Janux Therapeutics Inc (5 min.)




Is Janux Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$344.3m$338m-$12m-3.7%

How much money is Janux Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$14.5m-$13.7m-$832k-5.7%
Net Profit Margin-861.6%-674.0%--

How much money comes from the company's main activities?

3. Financial Health of Janux Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#160 / 1019

Most Revenue
#448 / 1019

Most Profit
#623 / 1019

Most Efficient
#799 / 1019

What can you expect buying and holding a share of Janux Therapeutics Inc? (5 min.)

Welcome investor! Janux Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Janux Therapeutics Inc.

What can you expect buying and holding a share of Janux Therapeutics Inc?

First you should know what it really means to hold a share of Janux Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Janux Therapeutics Inc is $47.96. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Janux Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Janux Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $6.67. Based on the TTM, the Book Value Change Per Share is $0.11 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.22 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Janux Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.23-0.5%-0.28-0.6%-0.31-0.6%-0.23-0.5%-0.23-0.5%
Usd Book Value Change Per Share-0.09-0.2%0.110.2%-0.22-0.5%0.511.1%0.511.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.09-0.2%0.110.2%-0.22-0.5%0.511.1%0.511.1%
Usd Price Per Share10.73-11.20-13.32-12.64-12.64-
Price to Earnings Ratio-11.79--10.19--11.05--13.99--13.99-
Price-to-Total Gains Ratio-120.53--56.99--60.94--64.11--64.11-
Price to Book Ratio1.61-1.79-2.04-1.88-1.88-
Price-to-Total Gains Ratio-120.53--56.99--60.94--64.11--64.11-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share47.96
Number of shares20
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.110.51
Usd Total Gains Per Share0.110.51
Gains per Quarter (20 shares)2.2910.25
Gains per Year (20 shares)9.1441.02
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
109-104131
2018808272
3027170123113
4037260164154
5046350205195
6055440246236
7064530287277
8073620328318
9082710369359
10091800410400

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.013.00.00.0%0.013.00.00.0%0.013.00.00.0%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%2.011.00.015.4%2.011.00.015.4%2.011.00.015.4%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.013.00.0%0.00.013.00.0%0.00.013.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%2.011.00.015.4%2.011.00.015.4%2.011.00.015.4%

Fundamentals of Janux Therapeutics Inc

About Janux Therapeutics Inc

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2024-04-11 12:23:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Janux Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Janux Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Janux Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -477.8% means that $-4.78 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Janux Therapeutics Inc:

  • The MRQ is -477.8%. The company is making a huge loss. -2
  • The TTM is -861.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-477.8%TTM-861.6%+383.8%
TTM-861.6%YOY-674.0%-187.6%
TTM-861.6%5Y-753.1%-108.5%
5Y-753.1%10Y-753.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-477.8%-197.2%-280.6%
TTM-861.6%-210.4%-651.2%
YOY-674.0%-279.3%-394.7%
5Y-753.1%-436.8%-316.3%
10Y-753.1%-599.3%-153.8%
1.1.2. Return on Assets

Shows how efficient Janux Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Janux Therapeutics Inc to the Biotechnology industry mean.
  • -3.1% Return on Assets means that Janux Therapeutics Inc generated $-0.03 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Janux Therapeutics Inc:

  • The MRQ is -3.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -4.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.1%TTM-4.0%+0.9%
TTM-4.0%YOY-3.7%-0.4%
TTM-4.0%5Y-4.0%0.0%
5Y-4.0%10Y-4.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.1%-13.6%+10.5%
TTM-4.0%-12.9%+8.9%
YOY-3.7%-11.9%+8.2%
5Y-4.0%-14.2%+10.2%
10Y-4.0%-16.2%+12.2%
1.1.3. Return on Equity

Shows how efficient Janux Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Janux Therapeutics Inc to the Biotechnology industry mean.
  • -3.4% Return on Equity means Janux Therapeutics Inc generated $-0.03 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Janux Therapeutics Inc:

  • The MRQ is -3.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-3.4%TTM-4.5%+1.1%
TTM-4.5%YOY-4.1%-0.5%
TTM-4.5%5Y-3.3%-1.3%
5Y-3.3%10Y-3.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.4%-17.0%+13.6%
TTM-4.5%-16.1%+11.6%
YOY-4.1%-15.4%+11.3%
5Y-3.3%-20.0%+16.7%
10Y-3.3%-21.1%+17.8%

1.2. Operating Efficiency of Janux Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Janux Therapeutics Inc is operating .

  • Measures how much profit Janux Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Janux Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of -655.7% means the company generated $-6.56  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Janux Therapeutics Inc:

  • The MRQ is -655.7%. The company is operating very inefficient. -2
  • The TTM is -1,069.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-655.7%TTM-1,069.8%+414.1%
TTM-1,069.8%YOY-808.1%-261.7%
TTM-1,069.8%5Y-859.1%-210.7%
5Y-859.1%10Y-859.1%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-655.7%-286.1%-369.6%
TTM-1,069.8%-224.4%-845.4%
YOY-808.1%-288.4%-519.7%
5Y-859.1%-475.2%-383.9%
10Y-859.1%-624.7%-234.4%
1.2.2. Operating Ratio

Measures how efficient Janux Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 7.77 means that the operating costs are $7.77 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Janux Therapeutics Inc:

  • The MRQ is 7.773. The company is inefficient in keeping operating costs low. -1
  • The TTM is 11.863. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ7.773TTM11.863-4.090
TTM11.863YOY11.507+0.356
TTM11.8635Y12.200-0.337
5Y12.20010Y12.2000.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.7732.997+4.776
TTM11.8633.247+8.616
YOY11.5073.766+7.741
5Y12.2005.675+6.525
10Y12.2007.857+4.343

1.3. Liquidity of Janux Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Janux Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 26.80 means the company has $26.80 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Janux Therapeutics Inc:

  • The MRQ is 26.797. The company is very able to pay all its short-term debts. +2
  • The TTM is 22.141. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ26.797TTM22.141+4.656
TTM22.141YOY24.478-2.337
TTM22.1415Y23.513-1.372
5Y23.51310Y23.5130.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ26.7973.930+22.867
TTM22.1414.251+17.890
YOY24.4785.436+19.042
5Y23.5136.045+17.468
10Y23.5136.363+17.150
1.3.2. Quick Ratio

Measures if Janux Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Janux Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 51.49 means the company can pay off $51.49 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Janux Therapeutics Inc:

  • The MRQ is 51.489. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 42.082. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ51.489TTM42.082+9.407
TTM42.082YOY44.370-2.288
TTM42.0825Y41.098+0.984
5Y41.09810Y41.0980.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ51.4893.629+47.860
TTM42.0824.065+38.017
YOY44.3705.397+38.973
5Y41.0985.993+35.105
10Y41.0986.277+34.821

1.4. Solvency of Janux Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Janux Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Janux Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.09 means that Janux Therapeutics Inc assets are financed with 9.5% credit (debt) and the remaining percentage (100% - 9.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Janux Therapeutics Inc:

  • The MRQ is 0.095. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.108. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.095TTM0.108-0.014
TTM0.108YOY0.095+0.014
TTM0.1085Y0.312-0.203
5Y0.31210Y0.3120.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0950.332-0.237
TTM0.1080.334-0.226
YOY0.0950.268-0.173
5Y0.3120.366-0.054
10Y0.3120.390-0.078
1.4.2. Debt to Equity Ratio

Measures if Janux Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Janux Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 10.5% means that company has $0.10 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Janux Therapeutics Inc:

  • The MRQ is 0.105. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.122. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.105TTM0.122-0.017
TTM0.122YOY0.106+0.016
TTM0.1225Y0.078+0.044
5Y0.07810Y0.0780.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1050.381-0.276
TTM0.1220.390-0.268
YOY0.1060.334-0.228
5Y0.0780.434-0.356
10Y0.0780.466-0.388

2. Market Valuation of Janux Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Janux Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Janux Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -11.79 means the investor is paying $-11.79 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Janux Therapeutics Inc:

  • The EOD is -52.679. Based on the earnings, the company is expensive. -2
  • The MRQ is -11.786. Based on the earnings, the company is expensive. -2
  • The TTM is -10.187. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-52.679MRQ-11.786-40.894
MRQ-11.786TTM-10.187-1.599
TTM-10.187YOY-11.052+0.866
TTM-10.1875Y-13.986+3.799
5Y-13.98610Y-13.9860.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-52.679-2.315-50.364
MRQ-11.786-2.560-9.226
TTM-10.187-2.664-7.523
YOY-11.052-4.122-6.930
5Y-13.986-6.258-7.728
10Y-13.986-6.108-7.878
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Janux Therapeutics Inc:

  • The EOD is -59.467. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -13.304. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -11.202. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-59.467MRQ-13.304-46.162
MRQ-13.304TTM-11.202-2.103
TTM-11.202YOY-15.149+3.947
TTM-11.2025Y-17.358+6.156
5Y-17.35810Y-17.3580.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-59.467-3.067-56.400
MRQ-13.304-3.251-10.053
TTM-11.202-3.545-7.657
YOY-15.149-5.595-9.554
5Y-17.358-8.315-9.043
10Y-17.358-8.708-8.650
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Janux Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.61 means the investor is paying $1.61 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Janux Therapeutics Inc:

  • The EOD is 7.195. Based on the equity, the company is overpriced. -1
  • The MRQ is 1.610. Based on the equity, the company is underpriced. +1
  • The TTM is 1.789. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD7.195MRQ1.610+5.585
MRQ1.610TTM1.789-0.180
TTM1.789YOY2.037-0.247
TTM1.7895Y1.877-0.088
5Y1.87710Y1.8770.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD7.1951.905+5.290
MRQ1.6102.111-0.501
TTM1.7892.095-0.306
YOY2.0372.836-0.799
5Y1.8773.443-1.566
10Y1.8773.794-1.917
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Janux Therapeutics Inc.

3.1. Institutions holding Janux Therapeutics Inc

Institutions are holding 82.349% of the shares of Janux Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31RA Capital Management, LLC17.74221.5361916565200
2023-12-31FMR Inc9.04220.00394671213-1680109-26.4529
2023-09-30Bvf Inc8.86531.2449457981847287311.514
2023-09-30Citadel Advisors Llc6.64190.00743431209131563562.1881
2023-12-31Orbimed Advisors, LLC6.42260.711331792700
2023-12-31HHG PLC3.73880.01241931477-135991-6.5777
2023-12-31BlackRock Inc3.4110.000517621011225227.4728
2023-12-31Adage Capital Partners Gp LLC2.62380.0301135547520547517.8674
2023-12-31Vanguard Group Inc1.8960.0002979483372023.9481
2023-12-31Geode Capital Management, LLC0.79010.0005408190213865.5289
2023-12-31Samsara BioCapital, LLC0.69770.601636041400
2023-12-31State Street Corporation0.67280.0002347585160144.8297
2023-12-31Northern Trust Corp0.39490.0004204002113175.8733
2023-09-30Alyeska Investment Group, L.P.0.33880.0121750001750000
2023-12-31Nuveen Asset Management, LLC0.15790.0003815741487222.2962
2023-12-31Goldman Sachs Group Inc0.15470.00017989665352449.3399
2023-12-31Millennium Management LLC0.13910.000371856-28756-28.5811
2023-12-31Morgan Stanley - Brokerage Accounts0.13060.00016744846992229.7223
2023-12-31Squarepoint Ops LLC0.11840.00126116850521474.5093
2023-12-31HPM Partners LLC0.11790.002260933609330
Total 64.09674.165433112421+771238+2.3%

3.2. Funds holding Janux Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Fidelity Growth Compy Commingled Pl O2.87650.0917148600651390052.8646
2024-02-29Fidelity Growth Company Fund1.62880.068284144910380014.0717
2024-02-29Vanguard Total Stock Mkt Idx Inv1.5360.002579351124500044.6664
2024-01-31Fidelity Small Cap Growth1.26370.0975652834-788-0.1206
2024-02-29Fidelity Select Health Care1.20980.38262500012500025
2023-12-31Janus Henderson Global Life Sciences D1.07990.1216557857-11819-2.0747
2023-12-31Janus Henderson Global Life Sciences1.07990.1222557857-11819-2.0747
2023-12-31Biotech Growth Ord1.02261.354252826100
2024-02-29Fidelity Advisor Health Care I0.82270.41324250007500021.4286
2024-03-28iShares Russell 2000 ETF0.81870.02434229362040.0483
2024-02-29Fidelity Advisor Biotechnology I0.7581.065339158500
2024-02-29Janus Henderson Glb Life Scn I2 USD0.75510.474339007834900.9028
2023-12-31Janus Selection Global Life Science AUSD0.74620.1118385468-39706-9.3388
2024-02-29Fidelity Select Biotechnology0.66140.3363341699218251176.7959
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr0.53960.0132278765179776.8933
2024-02-29Fidelity Growth Company K60.50580.06882612873210014.006
2024-02-29Lord Abbett Developing Growth A0.50470.5052607512607510
2024-03-28iShares Biotechnology ETF0.46930.11962424642996414.1007
2024-01-31Fidelity Small Cap Growth K60.4560.09442355697880.3356
2024-01-31Fidelity Small Cap Index0.34090.006117612813820.7909
Total 19.07565.47229854505+1563475+15.9%

3.3. Insider Transactions

Insiders are holding 13.776% of the shares of Janux Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2023-11-13Ventures Xi L.p. AvalonBUY8498545.87
2023-07-19Ra Capital Management, L.p.BUY49500812.46

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Janux Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.0890.114-178%-0.221+148%0.513-117%0.513-117%
Book Value Per Share--6.6666.311+6%6.543+2%5.588+19%5.588+19%
Current Ratio--26.79722.141+21%24.478+9%23.513+14%23.513+14%
Debt To Asset Ratio--0.0950.108-13%0.095+0%0.312-70%0.312-70%
Debt To Equity Ratio--0.1050.122-14%0.106-1%0.078+34%0.078+34%
Dividend Per Share----0%-0%-0%-0%
Eps---0.228-0.282+24%-0.305+34%-0.232+2%-0.232+2%
Free Cash Flow Per Share---0.202-0.254+26%-0.239+18%-0.181-10%-0.181-10%
Free Cash Flow To Equity Per Share---0.1860.034-638%-0.236+27%0.491-138%0.491-138%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---16.237--------
Intrinsic Value_10Y_min---13.759--------
Intrinsic Value_1Y_max---0.900--------
Intrinsic Value_1Y_min---0.884--------
Intrinsic Value_3Y_max---3.259--------
Intrinsic Value_3Y_min---3.100--------
Intrinsic Value_5Y_max---6.286--------
Intrinsic Value_5Y_min---5.786--------
Market Cap2477618396.000+78%554312873.000578334819.500-4%687854231.500-19%653102879.615-15%653102879.615-15%
Net Profit Margin---4.778-8.616+80%-6.740+41%-7.531+58%-7.531+58%
Operating Margin---6.557-10.698+63%-8.081+23%-8.591+31%-8.591+31%
Operating Ratio--7.77311.863-34%11.507-32%12.200-36%12.200-36%
Pb Ratio7.195+78%1.6101.789-10%2.037-21%1.877-14%1.877-14%
Pe Ratio-52.679-347%-11.786-10.187-14%-11.052-6%-13.986+19%-13.986+19%
Price Per Share47.960+78%10.73011.195-4%13.315-19%12.642-15%12.642-15%
Price To Free Cash Flow Ratio-59.467-347%-13.304-11.202-16%-15.149+14%-17.358+30%-17.358+30%
Price To Total Gains Ratio-538.730-347%-120.529-56.990-53%-60.936-49%-64.107-47%-64.107-47%
Quick Ratio--51.48942.082+22%44.370+16%41.098+25%41.098+25%
Return On Assets---0.031-0.040+31%-0.037+19%-0.040+30%-0.040+30%
Return On Equity---0.034-0.045+33%-0.041+19%-0.033-4%-0.033-4%
Total Gains Per Share---0.0890.114-178%-0.221+148%0.513-117%0.513-117%
Usd Book Value--344349000.000326007500.000+6%338037250.000+2%288664769.231+19%288664769.231+19%
Usd Book Value Change Per Share---0.0890.114-178%-0.221+148%0.513-117%0.513-117%
Usd Book Value Per Share--6.6666.311+6%6.543+2%5.588+19%5.588+19%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.228-0.282+24%-0.305+34%-0.232+2%-0.232+2%
Usd Free Cash Flow---10416000.000-13106250.000+26%-12341750.000+18%-9375307.692-10%-9375307.692-10%
Usd Free Cash Flow Per Share---0.202-0.254+26%-0.239+18%-0.181-10%-0.181-10%
Usd Free Cash Flow To Equity Per Share---0.1860.034-638%-0.236+27%0.491-138%0.491-138%
Usd Market Cap2477618396.000+78%554312873.000578334819.500-4%687854231.500-19%653102879.615-15%653102879.615-15%
Usd Price Per Share47.960+78%10.73011.195-4%13.315-19%12.642-15%12.642-15%
Usd Profit---11758000.000-14573250.000+24%-13741250.000+17%-11352692.308-3%-11352692.308-3%
Usd Revenue--2461000.0002020750.000+22%2153000.000+14%1564000.000+57%1564000.000+57%
Usd Total Gains Per Share---0.0890.114-178%-0.221+148%0.513-117%0.513-117%
 EOD+5 -3MRQTTM+23 -10YOY+27 -65Y+15 -1810Y+15 -18

4.2. Fundamental Score

Let's check the fundamental score of Janux Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-52.679
Price to Book Ratio (EOD)Between0-17.195
Net Profit Margin (MRQ)Greater than0-4.778
Operating Margin (MRQ)Greater than0-6.557
Quick Ratio (MRQ)Greater than151.489
Current Ratio (MRQ)Greater than126.797
Debt to Asset Ratio (MRQ)Less than10.095
Debt to Equity Ratio (MRQ)Less than10.105
Return on Equity (MRQ)Greater than0.15-0.034
Return on Assets (MRQ)Greater than0.05-0.031
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Janux Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5065.278
Ma 20Greater thanMa 5041.409
Ma 50Greater thanMa 10033.032
Ma 100Greater thanMa 20021.416
OpenGreater thanClose50.000
Total5/5 (100.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -1,535796-739-321-1,060-115-1,1751,840665



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets380,407
Total Liabilities36,058
Total Stockholder Equity344,349
 As reported
Total Liabilities 36,058
Total Stockholder Equity+ 344,349
Total Assets = 380,407

Assets

Total Assets380,407
Total Current Assets349,241
Long-term Assets31,166
Total Current Assets
Cash And Cash Equivalents 19,205
Short-term Investments 324,823
Net Receivables 2,200
Inventory -2,200
Other Current Assets 5,213
Total Current Assets  (as reported)349,241
Total Current Assets  (calculated)349,241
+/-0
Long-term Assets
Property Plant Equipment 27,841
Long-term Assets Other 2,509
Long-term Assets  (as reported)31,166
Long-term Assets  (calculated)30,350
+/- 816

Liabilities & Shareholders' Equity

Total Current Liabilities13,033
Long-term Liabilities23,025
Total Stockholder Equity344,349
Total Current Liabilities
Short-term Debt 1,517
Accounts payable 2,424
Other Current Liabilities 7,387
Total Current Liabilities  (as reported)13,033
Total Current Liabilities  (calculated)11,328
+/- 1,705
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt23,025
Long-term Liabilities  (as reported)23,025
Long-term Liabilities  (calculated)23,025
+/-0
Total Stockholder Equity
Common Stock46
Retained Earnings -168,763
Accumulated Other Comprehensive Income 665
Other Stockholders Equity 512,401
Total Stockholder Equity (as reported)344,349
Total Stockholder Equity (calculated)344,349
+/-0
Other
Capital Stock46
Cash and Short Term Investments 344,028
Common Stock Shares Outstanding 46,684
Current Deferred Revenue1,705
Liabilities and Stockholders Equity 380,407
Net Debt 5,337
Net Invested Capital 344,349
Net Working Capital 336,208
Property Plant and Equipment Gross 30,755
Short Long Term Debt Total 24,542



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-31
> Total Assets 
0
0
0
16,217
71,819
396,823
391,084
379,824
368,597
385,365
375,756
364,010
352,956
341,500
386,850
380,407
380,407386,850341,500352,956364,010375,756385,365368,597379,824391,084396,82371,81916,217000
   > Total Current Assets 
0
0
0
16,062
71,406
396,608
389,588
377,019
364,654
358,065
344,330
332,439
321,399
309,302
355,195
349,241
349,241355,195309,302321,399332,439344,330358,065364,654377,019389,588396,60871,40616,062000
       Cash And Cash Equivalents 
0
0
0
7,813
70,769
251,625
39,389
35,582
55,129
58,403
64,752
51,426
30,355
33,703
17,152
19,205
19,20517,15233,70330,35551,42664,75258,40355,12935,58239,389251,62570,7697,813000
       Short-term Investments 
0
0
0
0
0
142,570
348,118
339,383
306,071
295,893
274,008
275,590
286,520
269,586
332,560
324,823
324,823332,560269,586286,520275,590274,008295,893306,071339,383348,118142,57000000
       Net Receivables 
0
0
0
8,000
375
375
28
200
100
300
500
700
750
1,500
1,700
2,200
2,2001,7001,500750700500300100200283753758,000000
       Other Current Assets 
0
0
0
249
262
2,038
2,081
2,054
3,454
3,769
5,070
5,423
3,774
6,013
5,483
5,213
5,2135,4836,0133,7745,4235,0703,7693,4542,0542,0812,038262249000
   > Long-term Assets 
0
0
0
155
413
215
1,496
2,805
3,943
27,300
31,426
31,571
31,557
32,198
31,655
31,166
31,16631,65532,19831,55731,57131,42627,3003,9432,8051,496215413155000
       Property Plant Equipment 
0
0
0
155
156
215
1,356
1,597
2,790
26,277
29,177
29,365
29,130
28,949
28,525
27,841
27,84128,52528,94929,13029,36529,17726,2772,7901,5971,356215156155000
       Other Assets 
0
0
0
0
257
0
140
1,208
1,153
1,023
2,249
2,206
0
3,249
0
0
003,24902,2062,2491,0231,1531,20814002570000
> Total Liabilities 
0
0
0
30,855
88,590
12,028
14,334
13,497
12,515
41,551
44,243
43,270
41,692
42,031
37,902
36,058
36,05837,90242,03141,69243,27044,24341,55112,51513,49714,33412,02888,59030,855000
   > Total Current Liabilities 
0
0
0
3,181
6,894
9,205
12,471
12,797
12,515
12,994
16,335
16,507
16,114
17,904
14,471
13,033
13,03314,47117,90416,11416,50716,33512,99412,51512,79712,4719,2056,8943,181000
       Short-term Debt 
0
0
0
751
721
2,286
212
194
153
88
0
763
1,356
1,408
1,462
1,517
1,5171,4621,4081,3567630881531942122,286721751000
       Accounts payable 
0
0
0
428
857
354
3,613
2,458
1,939
3,000
2,866
2,159
2,051
1,910
2,505
2,424
2,4242,5051,9102,0512,1592,8663,0001,9392,4583,613354857428000
       Other Current Liabilities 
0
0
0
52
1,670
1,500
3,382
4,982
5,774
4,535
7,563
8,179
7,772
9,246
6,856
7,387
7,3876,8569,2467,7728,1797,5634,5355,7744,9823,3821,5001,67052000
   > Long-term Liabilities 
0
0
0
27,674
81,696
2,823
1,863
700
6,741
28,557
27,908
26,763
25,578
24,127
23,431
23,025
23,02523,43124,12725,57826,76327,90828,5576,7417001,8632,82381,69627,674000
       Other Liabilities 
0
0
0
0
4,350
2,823
1,840
700
0
5,289
3,816
2,221
0
307
0
0
0030702,2213,8165,28907001,8402,8234,3500000
> Total Stockholder Equity
0
0
0
-14,638
-16,771
384,795
376,750
366,327
356,082
343,814
331,513
320,740
311,264
299,469
348,948
344,349
344,349348,948299,469311,264320,740331,513343,814356,082366,327376,750384,795-16,771-14,638000
   Common Stock
0
0
0
1
1
41
41
41
41
42
42
42
42
42
46
46
464642424242424141414111000
   Retained Earnings Total Equity000-127,929-110,470-94,405-77,709-60,821-47,411-33,995-23,22900000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
17
24
-270
-1,567
-1,907
-2,277
-1,535
-739
-1,060
-1,175
665
665-1,175-1,060-739-1,535-2,277-1,907-1,567-270241700000
   Capital Surplus 
0
0
0
0
0
407,966
410,680
413,967
418,429
423,388
428,153
432,703
439,890
0
0
0
000439,890432,703428,153423,388418,429413,967410,680407,96600000
   Treasury Stock0000000000000000
   Other Stockholders Equity 
0
0
0
100
251
11,143
19,596
413,967
418,429
423,388
428,153
432,703
439,890
445,924
507,082
512,401
512,401507,082445,924439,890432,703428,153423,388418,429413,96719,59611,143251100000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue8,083
Cost of Revenue-1,955
Gross Profit6,1286,128
 
Operating Income (+$)
Gross Profit6,128
Operating Expense-81,062
Operating Income-72,979-74,934
 
Operating Expense (+$)
Research Development54,922
Selling General Administrative26,140
Selling And Marketing Expenses0
Operating Expense81,06281,062
 
Net Interest Income (+$)
Interest Income12,508
Interest Expense-0
Other Finance Cost-0
Net Interest Income12,508
 
Pretax Income (+$)
Operating Income-72,979
Net Interest Income12,508
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-58,293-87,665
EBIT - interestExpense = -72,979
-58,293
-58,293
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-72,979-58,293
Earnings Before Interest and Taxes (EBITDA)-71,024
 
After tax Income (+$)
Income Before Tax-58,293
Tax Provision-0
Net Income From Continuing Ops-62,600-58,293
Net Income-58,293
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses81,062
Total Other Income/Expenses Net14,686-12,508
 

Technical Analysis of Janux Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Janux Therapeutics Inc. The general trend of Janux Therapeutics Inc is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Janux Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Janux Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 58.69.

The bearish price targets are: 41.78 > 34.63 > 23.64.

Tweet this
Janux Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Janux Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Janux Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Janux Therapeutics Inc. The current macd is 4.3692573.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Janux Therapeutics Inc price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Janux Therapeutics Inc. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Janux Therapeutics Inc price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Janux Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartJanux Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Janux Therapeutics Inc. The current adx is 44.57.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Janux Therapeutics Inc shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
Janux Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Janux Therapeutics Inc. The current sar is 39.91.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Janux Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Janux Therapeutics Inc. The current rsi is 65.28. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending down: The RSI is trending down. -1
Janux Therapeutics Inc Daily Relative Strength Index (RSI) ChartJanux Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Janux Therapeutics Inc. The current phase is Continuation in bull market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Janux Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Janux Therapeutics Inc Daily Stochastic Oscillator ChartJanux Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Janux Therapeutics Inc. The current cci is 97.47.

Janux Therapeutics Inc Daily Commodity Channel Index (CCI) ChartJanux Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Janux Therapeutics Inc. The current cmo is 27.67.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Janux Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartJanux Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Janux Therapeutics Inc. The current willr is -38.40110906.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Janux Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Janux Therapeutics Inc Daily Williams %R ChartJanux Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Janux Therapeutics Inc.

Janux Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Janux Therapeutics Inc. The current atr is 4.13042959.

Janux Therapeutics Inc Daily Average True Range (ATR) ChartJanux Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Janux Therapeutics Inc. The current obv is 23,552,282.

Janux Therapeutics Inc Daily On-Balance Volume (OBV) ChartJanux Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Janux Therapeutics Inc. The current mfi is 71.94.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Janux Therapeutics Inc Daily Money Flow Index (MFI) ChartJanux Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Janux Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-24MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-27ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-29STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-17DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-22MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-05MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-08SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-03-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-12RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-03-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-10CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-04-15MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17RSI SHORT ENTRY LONG CLOSE70 crossover to downside

6.3. Candlestick Patterns

Janux Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Janux Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5065.278
Ma 20Greater thanMa 5041.409
Ma 50Greater thanMa 10033.032
Ma 100Greater thanMa 20021.416
OpenGreater thanClose50.000
Total5/5 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Janux Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Janux Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Janux Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Janux Therapeutics Inc

I send you an email if I find something interesting about Janux Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Janux Therapeutics Inc.

Receive notifications about Janux Therapeutics Inc in your mailbox!